LUND, Sweden I April 18, 2023 I Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the company presented a poster on ATOR-4066, a Neo-X-Prime™ bispecific antibody (bsAb), at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
CEACAM5, a well described clinical target for cancer therapy, is a glycoprotein that is overexpressed on the cell surface of many cancers including colorectal, gastric, pancreatic, and non-small cell lung cancer, with limited expression in normal adult tissue. Thus, it is an ideal target for a tumor-directed bispecific conditional CD40 agonistCD40 agonist like ATOR-4066.
The data demonstrate CEACAM5 expression in relevant indications and how ATOR-4066 induces:
"We are excited to be presenting new data from our novel Neo-X-Prime approach at this year's AACR meeting," said Søren Bregenholt, CEO of Alligator Bioscience. "We have already shown that simultaneously targeting CD40 and tumor associated antigens leads to superior anti-tumor immunity. These new data further demonstrate the ability of ATOR-4066 to remodel the immune microenvironment and, as it continues to show great potential in inducing strong anti-tumor responses in CEACAM5-expressing tumorsCEACAM5-expressing tumors, we remain committed to advancing ATOR-4066 towards the clinic."
Poster Presentation Details
Abstract Number: 2939
Title: ATOR-4066, a Neo-X-Prime™bispecific antibody targeting CD40 and CEO, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
Date/Time: Monday 17 April, 2023, 1.30 – 5.00 pm EDT
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.